Abstracts tagged "Quality Indicators"

Abstract Number: 1958 • ACR Convergence 2023
Validity, Responsiveness and Minimal Clinically Important Difference of EQ-5D-5L in Inflammatory Myositis: A Longitudinal Study
Chengappa Kavadichanda¹, Parthibane S¹, Mamatha Gorijavolu¹, Sai Kumar Dunga¹, Amrita Nayak¹, Sitanshu Sekhar¹ and Rohit Aggarwal², ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myositis (IIM) significantly impacts health-related quality of life (HRQoL). EQ5D-5L is a widely used and validated tool to measure HRQoL. The health…
Abstract Number: 2501 • ACR Convergence 2023
Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity
Jingru Tian¹, Shuntong Kang², Dingyao Zhang³ and Qianjin Lu⁴, ¹Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ²Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Nanjing, China, ³Graduate Program in Biological and Biomedical Sciences, Yale University, New Haven, CT, ⁴Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a common multisystem autoimmune disease with chronic inflammation. Many efficacy evaluation indicators of randomized clinical trials (RCTs) for SLE…
Abstract Number: 2537 • ACR Convergence 2023
Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Hailey Baker¹, Rebecca Fine¹, Fenn Suter², Heather Allore³, Betty Hsiao⁴, Vaidehi Chowdhary⁵, Elizabeth Lavelle⁶, Ping Chen⁶, Richard Hintz⁶, Lisa Suter⁷ and Abhijeet Danve⁸, ¹Yale New Haven Hospital, New Haven, CT, ²Georgetown University, Washington, DC, ³Yale University, Yale School of Medicine, New Haven, CT, ⁴Yale-New Haven Medical Center, New Haven, CT, ⁵Yale University, New Haven, CT, ⁶Yale New Haven Health, New Haven, CT, ⁷Yale School of Medicine, New Haven, CT, ⁸Yale University School of Medicine, Glastonbury, CT
Background/Purpose: Biologic and targeted synthetic DMARDs (b/tsDMARDs) are widely used to treat patients with various autoimmune inflammatory diseases (ARD). Use of a b/tsDMARD in patients…
Abstract Number: 0331 • ACR Convergence 2023
Assessment of Patient Adherence to “Sick Day Rules”: A Cross-sectional Study of Rheumatology Outpatients Prescribed Immunosuppressive Medications
Mervè Aksoy¹, Pamela Gonzalez Manrique², Heinrich-Karl Greenblatt¹ and Katarzyna Gilek-Seibert¹, ¹Roger Williams Medical Center, Providence, RI, ²Roger Williams Medical Center, North Providence, RI
Background/Purpose: Rheumatology outpatients receiving immunosuppressive medications (IS) inevitably develop acute infections. Expert guidance, in accordance with usual clinical practice, recommends counseling patients on “sick day…
Abstract Number: 111 • 2023 Pediatric Rheumatology Symposium
Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center
Omar Mostafa, Sharon Bout-Tabaku, Buthaina Al-Adba, Ahmad Kaddourah, Abubakr Imam, Ibrahim Shatat and Mohammed Yousuf Karim, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Hypogammaglobulinemia is an under-recognized complication of B-cell targeted therapies (BCTT) in both autoimmune diseases (AID) and malignancy. Hypogammaglobulinemia may be transient or persistent, and…
Abstract Number: 131 • 2023 Pediatric Rheumatology Symposium
Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative
Jayne MacMahon¹, Jeanine McColl², Alaa Al-Shehab¹, Deborah Levy³, Ronald laxer¹ and Shirley Tse¹, ¹University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ²University of Alberta, Edmonton, AB, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Prescribing methotrexate,is common practice in rheumatology. Appropriate medication counselling and documentation is important. In our province, as per thephysician regulatory body the College of…
Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Farah Shaya, Sharon Bout-Tabaku and Buthaina Al-Adba, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…
Abstract Number: 0065 • ACR Convergence 2022
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
Tarun Sharma¹, paul lebovitz¹, chetan rajput², Lori Mcaninch³, ellen Kraemer³, izabela Stanescu³, adam dore¹, joseph ahearn³ and Susan Manzi⁴, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, ³Allegheny Health Network, Pittsburgh, ⁴Allegheny Health Network, Lupus Center of Excellence, Wexford, PA
Background/Purpose: Care transformation in a chronic illness like RA requires delivery of health care services through a patient-centric care model. Within an integrated delivery and…
Abstract Number: 0572 • ACR Convergence 2022
ACR Workgroup to Develop Recommendations for PRO Use in Clinical Care for SLE
Patricia Katz¹, Claire Barber², Ali Duarte-Garcia³, Shivani Garg⁴, Wambui Machua⁵, Yesenia Santiago-Casas⁶, Wendy Rodgers⁷, Lisa Suter⁸, Jennifer Ude⁹, Tracy Johansson⁹, Christie Bartels¹⁰ and Jinoos Yazdany¹¹, ¹UCSF, San Rafael, CA, ²University of Calgary, Calgary, AB, Canada, ³Mayo Clinic, Rochester, MN, ⁴University of Madison, School of Medicine and Public Health, Madison, WI, ⁵Piedmont Physicians, Rheumatology, Atlanta, GA, ⁶Integral Rheumatology and Immunology Specialists, Plantation, FL, ⁷Lupus Foundation of America, Torrance, CA, ⁸Yale School of Medicine, New Haven, CT, ⁹American College of Rheumatology, Atlanta, GA, ¹⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹¹UCSF, San Francisco, CA
Background/Purpose: Patient-reported outcome (PRO) measures are not consistently used in clinical settings for patients with systemic lupus erythematosus (SLE). As part of a Centers for…
Abstract Number: 1267 • ACR Convergence 2022
Accuracy of Financial Disclosures in American-Based Rheumatology Journals
Mary Guan¹, Michael Pillinger² and Aryeh Abeles³, ¹New York University Grossman School of Medicine, Brooklyn, NY, ²NYU Grossman School of Medicine, New York, NY, ³New York University Grossman School of Medicine, Wallingford, CT
Background/Purpose: Prior studies demonstrated that authors of publications may not accurately disclose their financial relationships with industry. One recent study reported that among authors of…
Abstract Number: 1273 • ACR Convergence 2022
Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: Data Availability and Preliminary Measure Performance in the RISE Registry
April Jorge¹, Alfredo Aguirre², April Barnado³, Bonnie Bermas⁴, Candace Feldman⁵, Shraddha Jatwani⁶, Alex Limanni⁷, JoAnn Zell⁸, Claire Barber⁹, Ali Duarte-Garcia¹⁰, Shivani Garg¹¹, Jing Li², Gabriela Schmajuk¹², Jinoos Yazdany¹³ and Christie Bartels¹⁴, ¹Massachusetts General Hospital, Boston, MA, ²University of California, San Francisco, San Francisco, CA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴UT Southwestern, Dallas, TX, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Albert Einstein Medical Center, Ambler, PA, ⁷Self, Dallas, TX, ⁸University of Colorado Anschutz Medical Campus, Denver, CO, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Mayo Clinic, Rochester, MN, ¹¹University of Madison, School of Medicine and Public Health, Madison, WI, ¹²UCSF / SFVA, San Francisco, CA, ¹³UCSF, San Francisco, CA, ¹⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Digital quality measures can facilitate monitoring and improvement of health care quality on a population level. As part of a CDC-funded ACR initiative to…
Abstract Number: 1277 • ACR Convergence 2022
Improving Patient Appropriate Osteoporosis Screening with Dual Energy X-ray Absorptiometry Scans in an Academic Internal Medicine Practice
Nithin Pusapati¹, Rebecca Fitzpatrick¹, Manya Gupta¹ and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Nearly 53.6 million people in America have osteoporosis with increasing incidence each year (Brauer, JAMA 2009). Almost 25% of people with a hip fracture…
Abstract Number: 1280 • ACR Convergence 2022
Patients with Systemic Lupus Erythematosus Perceive the Quality of Care They Receive to Be Suboptimal
Sidha Sreedharan¹, Geoffrey Littlejohn², Russell Buchanan³, Mandana Nikpour⁴, Eric Morand⁵, Alberta Hoi⁶ and Vera Golder⁷, ¹Monash Health, North Melbourne, Australia, ²OPAL Rheumatology Ltd, Melbourne, Australia, ³Austin Health, Heidelberg, Australia, ⁴The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ⁶Monash Health, Melbourne, Australia, ⁷Monash University, Clayton, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease associated with frequent healthcare interactions. The Chronic Care Model is a widely accepted framework…
Abstract Number: 1297 • ACR Convergence 2022
A Paediatric-Adult Provider Dyad Care Model Improves Transition from Paediatric to Adult Health Care for Youth with Childhood-Onset Systemic Lupus Erythematosus
Tala El Tal¹, Abdulaziz el Mutairi¹, Amanda Steiman² and Earl Silverman³, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²Sinai Health System, Toronto, ON, Canada, ³The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease affecting 1 in 1000 individuals, of whom 20% develop the disease in childhood. Childhood-onset…
Abstract Number: 1298 • ACR Convergence 2022
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
Catherine Bingham¹, Julia Harris², Sheetal Vora³, Mileka Gilbert⁴, Cagri Yildirim-Toruner⁵, Kerry Ferraro⁶, Tingting Qiu⁷, Jon Burnham⁸, Michelle Batthish⁹, Beth Gottlieb¹⁰, Daniel Lovell⁷, Ronald Laxer¹¹, Tzielan Lee¹², Danielle Bullock¹³, Charles H Spencer¹⁴, Jennifer Weiss¹⁵, Melissa Hazen¹⁶, Edward Oberle¹⁷, Melissa Mannion¹⁸, Nancy Pan¹⁹, Michael Shishov²⁰, Danielle Fair²¹, Mary Toth²², Kendra Wiegand⁷ and Esi Morgan²³, ¹Penn State Children's Hospital, Hershey, PA, ²Children's Mercy Kansas City, Overland Park, KS, ³Atrium Health Levine Children's, Charlotte, NC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Texas Children's Hospital/ Baylor College of Medicine, Houston, TX, ⁶Pediatric Rheumatology Care and Outcomes Improvement Network, Philadelphia, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³University of Minnesota, Minneapolis, MN, ¹⁴Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, ¹⁵Hackensack University Medical Center, Hackensack, NJ, ¹⁶Boston Children's Hospital, Boston, MA, ¹⁷Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ¹⁸University of Alabama at Birmingham, Birmingham, AL, ¹⁹Hospital for Special Surgery, New York, NY, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ²²Nemours Foundation, Orlando, FL, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a Learning Health Network designed to improve outcomes of care for children with juvenile idiopathic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].